131 withdrawn. 131 Phase 2, 31 Phase 1, 12 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 131 | Withdrawn 131 |
| Phase 1 | 31 | Withdrawn 31 |
| Phase 3 | 12 | Withdrawn 12 |
Follow Liver Diseases: new trials by email Literature Review of Liver Diseases trials Research Report on Liver Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma Regorafenib, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization - Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma | Phase 2 | Withdrawn | University of Miami | 2026-08-01 | 2026-06-15 | |
| BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma BC3402, Durvalumab, Tremelimumab - Hepato Cellular Carcinoma (HCC) | Phase 1 / Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2025-11-01 | 2026-02-19 | |
| A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma Radiation Therapy, Tremelimumab, Durvalumab - Hepatocellular Carcinoma (HCC) | Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2025-10-01 | 2025-11-18 | |
| A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine - Gastrointestinal Carcinoma, Pancreatic Cancer | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-09-09 | 2025-09-11 | |
| A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects TQA3605 tablets Placebo, TQA3605 Tablets, Entecavir dispersible tablets - Chronic Hepatitis B | Phase 2 | Withdrawn | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-07-09 | 2025-08-03 | |
| NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease Biological NTLA-3001 - Lung Disease, Pulmonary Disease | Phase 1 / Phase 2 | Withdrawn | Intellia Therapeutics | 2024-11-20 | 2025-01-17 | |
| Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC Cadonilimab+Lenvatinib - Hepatocellular Carcinoma | Phase 2 | Withdrawn | Shanghai Zhongshan Hospital | 2024-05-31 | 2025-05-23 | |
| Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis Peginterferon Lambda - Chronic Hepatitis Delta | Phase 2 | Withdrawn | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2024-05-22 | 2024-05-23 | |
| Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection Imdusiran, Durvalumab - Hepatitis B, Chronic | Phase 2 | Withdrawn | Arbutus Biopharma Corporation | 2024-05-01 | 2024-08-12 | |
| Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy Cemiplimab - Hepatitis B Virus | Phase 1 / Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-01-01 | 2023-09-07 | |
| Y-90 Versus SBRT for Inoperable HCC Quality of Life, Questionnaire Administration, Stereotactic Body Radiation Therapy - Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8 | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2023-12-01 | 2023-03-23 | |
| A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease PRIM-DJ2727, Placebo - Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus | Phase 2 | Withdrawn | The University of Texas Health Science Center, Houston | 2023-12-01 | 2024-05-14 | |
| Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH ASC41 2 mg, ASC41 4 mg, Placebo - Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Withdrawn | Gannex Pharma Co., Ltd. | 2023-12-01 | 2024-09-27 | |
| The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure MSC-EVs - Acute-On-Chronic Liver Failure, Acute Liver Failure | Phase 1 / Phase 2 | Withdrawn | Third Affiliated Hospital, Sun Yat-Sen University | 2023-09-01 | 2023-10-12 | |
| A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma Atezolizumab, Bevacizumab, ADI-PEG 20 - Metastatic Hepatocellular Carcinoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2023-08-08 | 2024-08-26 | |
| A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy Cabozantinib, Nivolumab - Hepatocellular Carcinoma, Liver Cancer | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2023-02-24 | 2023-05-12 | |
| BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases 4-Phenylbutyrate - Hereditary Diseases, Cholestasis, Intrahepatic | Phase 2 / Phase 3 | Withdrawn | Children's Hospital of Fudan University | 2023-02-08 | 2023-02-09 | |
| TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors TT-4 - Colorectal Cancer, Gastric Cancer | Phase 1 / Phase 2 | Withdrawn | Tarus Therapeutics, Inc. | 2022-12-15 | 2025-03-18 | |
| Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma Atezolizumab, Biopsy, Cabozantinib S-malate - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2022-12-10 | 2022-12-14 | |
| Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T Candonilimab, Bevacizumab - Hepatocellular Carcinoma | Phase 2 | Withdrawn | Shi Ming | 2022-12-07 | 2023-06-02 |
Showing 20 of 131. Sign in to see all of them.
Carcinoma, Hepatocellular (63) · Liver Neoplasms (19) · Hepatitis C (14) · Non-alcoholic Fatty Liver Disease (10) · Hepatitis B, Chronic (8) · Colorectal Neoplasms (5) · Hepatitis B (5) · alpha 1-Antitrypsin Deficiency (5) · Fibrosis (4) · Liver Cirrhosis (4) · Liver Failure (4) · Neoplasm Metastasis (4) · Pancreatic Neoplasms (4) · Diabetes Mellitus, Type 2 (3)
Digestive System Diseases (131) · Digestive System Neoplasms (71) · Neoplasms by Site (71) · Neoplasms (70) · Adenocarcinoma (64) · Neoplasms by Histologic Type (64) · Neoplasms, Glandular and Epithelial (64) · Carcinoma (63) · Liver Neoplasms (52) · Pathologic Processes (34) · Pathological Conditions, Signs and Symptoms (34) · Hepatitis (29) · Hepatitis, Viral, Human (27) · Infections (27)
Ribavirin (7) · Sorafenib (7) · Oxaliplatin (6) · Fluorouracil (5) · lenvatinib (5) · peginterferon alfa-2a (5) · spartalizumab (5) · Gemcitabine (4) · Bevacizumab (3) · Folfox protocol (3) · Leucovorin (3) · Radiosurgery (3) · Ritonavir (3) · Ursodeoxycholic Acid (3) · atezolizumab (3)
Sun Yat-sen University (6) · Guangxi Medical University (4) · Washington University School of Medicine (4) · Bristol-Myers Squibb (3) · Case Comprehensive Cancer Center (3) · M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Shi Ming (3) · Arrowhead Pharmaceuticals (2) · Eli Lilly and Company (2) · Fuda Cancer Hospital, Guangzhou (2) · Jonsson Comprehensive Cancer Center (2) · Mirror Biologics, Inc. (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2)
United States (38) · China (23) · Canada (7) · France (5) · Israel (4) · Spain (4) · Egypt (3) · Taiwan (3) · Germany (2) · Hong Kong (2) · New Zealand (2) · Thailand (2) · United Kingdom (2) · Australia (1) · Belgium (1)
Ming Shi, MD (6) · Lequn Li, PhD (3) · Juan Sanabria (2) · Robert A Ashley (2) · Steven Strasberg, M.D. (2) · A. Craig Lockhart, M.D. (1) · Adel Kardosh, M.D., Ph.D. (1) · AeRang Kim, MD, PhD (1) · Alan P. Venook, MD (1) · Andrew M Courtwright, MD, PhD (1) · Anne-Sophie Sejling, MD (1) · Antoni Ribas, MD (1) · Brian G Harbrecht, MD (1)
PMID 14762849, PMID 18565579, PMID 18834631, PMID 21058409, PMID 21123824, PMID 22075702, PMID 22412837, PMID 23607614, PMID 23734882, PMID 23786302, PMID 23829627, PMID 23980077, PMID 24708667, PMID 26155840, PMID 26690886, PMID 27439433, PMID 27908546, PMID 28951631, PMID 29389088, PMID 29414684, PMID 30251931
2019 (4), 2015 (2), 2014 (1), 2016 (1), 2017 (1), N01CM00070 (1), P01CA203628 (1), P30CA012197 (1), P30CA016672 (1), P30CA043703 (1), P30DK034989 (1), U01CA070172 (1)